Structure Therapeutics (GPCR) EPS (Weighted Average and Diluted) (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly EPS (Weighted Average and Diluted) of -$0.35 in Q1 2026, down 275.0% quarter-over-quarter from $0.2 in Q4 2025, and down 29.63% on a YoY basis from -$0.5 in Q1 2025.
Structure Therapeutics (GPCR) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Structure Therapeutics' EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at -$0.35 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 29.63% year-over-year to -$0.35; the TTM figure through Mar 2026 stood at -$0.88 (down 1.15% YoY), while the FY2025 annual figure was -$0.8, down 2.56% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.35 for Q1 2026 at Structure Therapeutics, down from $0.2 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.2 in Q4 2025 to a low of -$1.64 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.49 across 5 years, with a median of -$0.25 in 2023.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 190.91% in 2025; the steepest drop was 100.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.17 in 2022, then soared by 86.32% to -$0.16 in 2023, then sank by 37.5% to -$0.22 in 2024, then soared by 190.91% to $0.2 in 2025, then plunged by 275.0% to -$0.35 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.35 (Q1 2026), $0.2 (Q4 2025), and -$0.37 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | -0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | 0.20 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -0.36 |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | -0.22 |
| Sep 30, 2024 | -0.20 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.19 |
| Dec 31, 2023 | -0.16 |
| Sep 30, 2023 | -0.21 |
| Jun 30, 2023 | -0.20 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | -1.17 |
| Sep 30, 2022 | -1.27 |
| Jun 30, 2022 | -1.64 |
| Mar 31, 2022 | -1.44 |